Search research articles
Contact Us
Filters
Showing results (81-90 of 104) with videos related to
Page
of 11
Sort By:
The Journal of Urology
|
December 18, 2007
The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study
Claus G Roehrborn, Paul Siami, Jack Barkin, et al.
BJU International
|
October 17, 2013
Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study
Claus G Roehrborn, Jack Barkin, Andrea Tubaro, et al.
The Canadian Journal of Urology
|
March 7, 2017
Improving prostate cancer care collaboratively - a multidisciplinary, formal, consensus-based approach
Andrew Loblaw, Jack Barkin, Roger Buckley, et al.
BJU International
|
February 22, 2011
Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial
Claus G Roehrborn, Jack Barkin, Paul Siami, et al.
Contemporary Clinical Trials
|
September 1, 2007
Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design
Paul Siami, Claus G Roehrborn, Jack Barkin, et al.
European Urology
|
December 25, 2016
Corrigendum to: "The Influence of Baseline Parameters on Changes in IPSS with Dutasteride, Tamsulosin, and Combination Therapy: Two-Year Data from the Combination of Avodart<sup>®</sup> and Tamsulosin (CombAT) Study" [Eur Urol Suppl 2008;7:171 (Abstract no. 403)]
Claus G Roehrborn, Andrea Tubaro, Francesco Montorsi, et al.
Clinical Therapeutics
|
September 1, 2004
A randomized, double-blind, parallel-group comparison of controlled- and immediate-release oxybutynin chloride in urge urinary incontinence
Jack Barkin, Jacques Corcos, Sidney Radomski, et al.
The Canadian Journal of Urology
|
December 15, 2011
Results of high intensity focused ultrasound treatment of prostate cancer: early Canadian experience at a single center
Dean S Elterman, Jack Barkin, Sidney B Radomski, et al.
European Urology
|
November 18, 2008
The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study
Claus G Roehrborn, Paul Siami, Jack Barkin, et al.
Urology
|
March 22, 2017
Adding Mirabegron to Solifenacin to Treat Overactive Bladder Has Little Impact on Postvoid Residual Volume or Urinary Retention Risk
Marcus J Drake, Scott MacDiarmid, Salman Al-Shukri, et al.
Page
of 11
Search research articles
Search
Showing results (81-90 of 104) with videos related to
Sort By:
Page
of 11
The Journal of Urology
|
December 18, 2007
The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study
Claus G Roehrborn, Paul Siami, Jack Barkin, et al.
BJU International
|
October 17, 2013
Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study
Claus G Roehrborn, Jack Barkin, Andrea Tubaro, et al.
The Canadian Journal of Urology
|
March 7, 2017
Improving prostate cancer care collaboratively - a multidisciplinary, formal, consensus-based approach
Andrew Loblaw, Jack Barkin, Roger Buckley, et al.
BJU International
|
February 22, 2011
Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial
Claus G Roehrborn, Jack Barkin, Paul Siami, et al.
Contemporary Clinical Trials
|
September 1, 2007
Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design
Paul Siami, Claus G Roehrborn, Jack Barkin, et al.
European Urology
|
December 25, 2016
Corrigendum to: "The Influence of Baseline Parameters on Changes in IPSS with Dutasteride, Tamsulosin, and Combination Therapy: Two-Year Data from the Combination of Avodart<sup>®</sup> and Tamsulosin (CombAT) Study" [Eur Urol Suppl 2008;7:171 (Abstract no. 403)]
Claus G Roehrborn, Andrea Tubaro, Francesco Montorsi, et al.
Clinical Therapeutics
|
September 1, 2004
A randomized, double-blind, parallel-group comparison of controlled- and immediate-release oxybutynin chloride in urge urinary incontinence
Jack Barkin, Jacques Corcos, Sidney Radomski, et al.
The Canadian Journal of Urology
|
December 15, 2011
Results of high intensity focused ultrasound treatment of prostate cancer: early Canadian experience at a single center
Dean S Elterman, Jack Barkin, Sidney B Radomski, et al.
European Urology
|
November 18, 2008
The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study
Claus G Roehrborn, Paul Siami, Jack Barkin, et al.
Urology
|
March 22, 2017
Adding Mirabegron to Solifenacin to Treat Overactive Bladder Has Little Impact on Postvoid Residual Volume or Urinary Retention Risk
Marcus J Drake, Scott MacDiarmid, Salman Al-Shukri, et al.
Page
of 11